Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.82 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.82 |
| ▸ | FLT1 | P17948 | 11/20 | 0.82 |
| ▸ | EGFR | P00533 | 11/20 | 0.74 |
| ▸ | FLT4 | P35916 | 8/20 | 0.74 |
| ▸ | RET | P07949 | 3/20 | 0.69 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.64 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19220790 | 0.95 | EGFR (0.81) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL19220780 | 0.95 | EGFR (0.77) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL17520347 | 0.91 | KDR (0.82) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL1467348 | 0.90 | FLT1 (1.00) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL17520359 | 0.86 | KDR (0.87) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL1468087 | 0.86 | FGFR1 (0.98) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL17520350 | 0.86 | KDR (0.82) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL17520326 | 0.86 | EGFR (0.85) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL7865988 | 0.86 | KDR (0.80) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL1467339 | 0.85 | FLT1 (0.90) | KDRFGFR1FLT1EGFRFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | KDR 3669/4885FGFR1 4724/4885FLT1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.